Efavirenz 600mg

DRUG8 trials

Conditions

HIVHIV InfectionsHivHuman Immunodeficiency Virus InfectionsNon-Hodgkin's LymphomaPancreatic CancerSolid TumorsTuberculosis

Phase 1

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

CompletedNCT01878890

Institut BergoniéNon-Hodgkin's Lymphoma, Solid Tumors

Start: 2011-09-05End: 2016-12-31Updated: 2021-01-27

Phase 2

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

CompletedNCT00964171

Institut BergoniéPancreatic Cancer

Start: 2008-08-31End: 2010-07-31Updated: 2025-08-28

Phase 3

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

CompletedNCT00727597

Georgetown UniversityHuman Immunodeficiency Virus Infections

Start: 2008-07-31End: 2011-07-31Updated: 2013-07-02

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

CompletedNCT01011413

Kirby InstituteHIV Infections

Start: 2011-08-31End: 2014-08-31Updated: 2020-02-21

Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients

NCT04513379

Shanghai Public Health Clinical CenterHIV Infections, Tuberculosis

Start: 2020-11-01End: 2023-01-31Target: 80Updated: 2020-08-14

Phase 4

Efavirenz (EFV) Intensification

CompletedNCT07193875

Washington University School of MedicineHIV

Start: 2023-02-09End: 2024-12-16Updated: 2025-09-26

Unknown Phase

Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

CompletedNCT01410058

University of ZimbabweHIV

Start: 2013-01-31End: 2013-09-30Updated: 2019-04-02

The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY

RecruitingNCT06823596

University of TorontoHiv

Start: 2025-01-14End: 2028-11-15Target: 26Updated: 2026-03-17

AIDS Research and Therapy2017-03-1441 citations

Capacity for ethical and regulatory review of herbal trials in developing countries: a case study of Moringa oleifera research in HIV-infected patients

Journal of Pharmaceutical Policy and Practice2017-02-2010 citations

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

2015-04-1281 citations

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Clinical Infectious Diseases2014-12-1129 citations

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

2014-02-10116 citations

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.

2013-06-0713 citations